Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAmneal Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | $0.14 | $0.17 | $0.16 |
Amneal Pharmaceuticals, Inc. Earnings Date And Information
Amneal Pharmaceuticals, Inc. last posted its earnings results on Friday, February 28th, 2025. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by $0.03. The company had revenue of 730.52 M for the quarter and had revenue of 2.79 B for the year. Amneal Pharmaceuticals, Inc. has generated $0 earnings per share over the last year ($-0.38 diluted earnings per share) and currently has a price-to-earnings ratio of -23.54. Amneal Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 7th, 2025 based on prior year's report dates.
Amneal Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/28/2025 | Q4 2024 | $0.15 | -$0.10 | -0.25 | $707.40 M | $730.52 M |
| 11/12/2024 | Q3 2024 | N/A | $0.04 | N/A | $690.23 M | $702.47 M |
| 08/09/2024 | Q2 2024 | $0.14 | $0.02 | -0.12 | $657.52 M | $701.78 M |
| 05/08/2024 | Q1 2024 | N/A | -$0.30 | N/A | N/A | $659.19 M |
| 03/14/2024 | Q4 2023 | N/A | -$0.40 | N/A | $630.67 M | $616.98 M |
| 11/08/2023 | Q3 2023 | N/A | $0.06 | N/A | $602.60 M | $620.04 M |
| 08/08/2023 | Q2 2023 | N/A | $0.08 | N/A | N/A | $599.05 M |
| 05/09/2023 | Q1 2023 | N/A | -$0.07 | N/A | N/A | $557.54 M |
| 03/03/2023 | Q4 2022 | N/A | -$0.04 | N/A | N/A | $609.76 M |
| 11/07/2022 | Q3 2022 | N/A | -$0.02 | N/A | N/A | $545.56 M |
| 08/08/2022 | Q2 2022 | N/A | -$0.80 | N/A | N/A | $559.36 M |
| 05/06/2022 | Q1 2022 | N/A | -$0.04 | N/A | N/A | $497.63 M |
| 03/01/2022 | Q4 2021 | N/A | -$0.04 | N/A | N/A | $536.90 M |
| 11/08/2021 | Q3 2021 | N/A | -$0.03 | N/A | N/A | $528.59 M |
| 08/09/2021 | Q2 2021 | $0.18 | $0.10 | -0.08 | N/A | $535.08 M |
| 05/07/2021 | Q1 2021 | $0.18 | $0.05 | -0.13 | N/A | $493.11 M |
| 03/01/2021 | Q4 2020 | N/A | -$0.02 | N/A | N/A | $510.03 M |
| 11/06/2020 | Q3 2020 | $0.13 | -$0.06 | -0.19 | N/A | $519.29 M |
| 08/06/2020 | Q2 2020 | $0.10 | -$0.08 | -0.18 | N/A | $464.66 M |
| 05/11/2020 | Q1 2020 | $0.08 | $0.78 | 0.7 | N/A | $498.53 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Amneal Pharmaceuticals, Inc. Earnings: FAQ's
Amneal Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 7th, 2025 based offlast year's report dates.
The conference call for Amneal Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Amneal Pharmaceuticals, Inc.'s latest earnings report can be read online.
Amneal Pharmaceuticals, Inc. (:AMRX) has a recorded annual revenue of $2.79 B.
Amneal Pharmaceuticals, Inc. (:AMRX) has a recorded net income of $-116,886,000.Amneal Pharmaceuticals, Inc. has generated $-0.38 earnings per share over the last four quarters.
Amneal Pharmaceuticals, Inc. (:AMRX) has a price-to-earnings ratio of -23.54 and price/earnings-to-growth ratio is -0.5.